Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
The double-blind, U.S. Phase II Spruce trial in about 155 patients with previously untreated metastatic non-squamous NSCLC showed that once-weekly 600 mg IV apatorsen plus carboplatin and Alimta peme...